Adjuvante Therapie des Kolonkarzinoms
详细信息 查看全文
- 作者：Prof. Dr. H. Algül ; R. M. Schmid
- 关键词：SchlüsselwörterAdjuvante Chemotherapie ; Mikrosatelliteninstabilität ; Tumorstaging ; Molekulare gezielte Therapie ; 5 ; Fluoropyrimidin
- 刊名：Der Gastroenterologe
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：11
- 期：6
- 页码：456-463
- 全文大小：316 KB
- 刊物主题：Gastroenterology; General Practice / Family Medicine; Internal Medicine; Hepatology; Infectious Diseases; Oncology;
- 出版者：Springer Berlin Heidelberg
- ISSN：1861-969X
- 卷排序：11
文摘
Since its establishment 30 years ago, adjuvant chemotherapy for colon cancer has reduced the relapse rate and improved survival of patients after surgery. Adjuvant chemotherapy is therefore generally recommended in stage III tumors. By contrast, its benefit for stage II cancer in terms of survival benefit is questionable. The evaluation of various clinical trials identified factors that allow risk stratification for stage II. Accordingly, stage II colon cancer with microsatellite instability should be only followed up after curative surgery. Not only microsatellite instability, but also tumor location determine the prognosis of BRAF or KRAS mutant stage III. With the increasing knowledge on colon cancer, future developments will be directed towards a more stage-specific and individualized adjuvant therapy of colon cancer.